Roche Diagnostics at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
Roche Diagnostics takes part in 7 sessions at CTAD 2026 in Boston. Its program centres on the Elecsys blood and CSF assays and how they fit into clinical care. Its work covers pTau217 cutoffs across care settings, the economics of blood-based testing in primary care and assay interference in TDP-43 tests.
| Organization | CTAD 2026 Attendance |
|---|---|
Roche Diagnostics Rotkreuz, Switzerland | |
Roche's diagnostics business; makes Elecsys CSF and plasma pTau217 immunoassays used to detect Alzheimer's amyloid pathology. | Poster Wed Nov 18 7:15am–5:30pm Poster Wed Nov 18 7:15am–5:30pm Poster Wed Nov 18 7:15am–5:30pm Poster Wed Nov 18 7:15am–5:30pm Poster Wed Nov 18 7:15am–5:30pm Poster Wed Nov 18 7:15am–5:30pm |
Instantly find 20 buyers from Roche Diagnostics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction